Contact
searchSearch
HMP Global

Advertisement

Advertisement

ADVERTISEMENT

Diabetic Macular Edema Topic Center

Featured

News
Balancing Medicare Advantage Denials for Patients With Diabetic Macular Edema
03/04/2024

Emry Lloyd

Emry Lloyd
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of...
03/04/2024
First Report Managed Care
News
Subthreshold Micropulse Laser Equivalent to Standard Laser Therapy for DME
01/10/2024
Jolynn Tumolo
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser...
01/10/2024
First Report Managed Care
News
Response to First Anti-VEGF Injection for DME Predicts Long-term Effects of Therapy
11/21/2022
Jolynn Tumolo
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial...
11/21/2022
First Report Managed Care
News
Retinal Thickness Lower With Intravitreal Steroids for Diabetic Macular Edema
11/09/2022
Jolynn Tumolo
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the...
11/09/2022
First Report Managed Care
News
Treatment More Effective Than Laser Photocoagulation for Improving Diabetic Macular Edema
10/24/2022
Jolynn Tumolo
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy...
10/24/2022
First Report Managed Care
News
Anti-VEGF Treatment Changes Aqueous Cytokine Levels in Patients With DME
10/21/2022
Edan Stanley
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the...
10/21/2022
First Report Managed Care
News
Cataract Surgery Outcomes Unaffected by Intravitreal Aflibercept for Diabetic Macular Edema
09/21/2022
Jolynn Tumolo
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept,...
09/21/2022
First Report Managed Care
News
Intravitreal VEGF Inhibitors Associated With HbA1c Reduction for Patients With DME
09/14/2022
Maria Asimopoulos
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact...
09/14/2022
First Report Managed Care
News
Preoperative Bevacizumab Benefits Patients With Diabetes With Vitreous Hemorrhage Without Tractional Detachment
06/02/2022
Jolynn Tumolo
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood...
06/02/2022
First Report Managed Care
News
Study Compares 3 Drugs for Diabetic Macular Edema
02/19/2015
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs...
02/19/2015
First Report Managed Care
News
FDA Approves Drug for Diabetic Retinopathy with Diabetic Macular Edema
02/09/2015
The FDA approved ranibizumab injection 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema.
The FDA approved ranibizumab injection 0.3 mg to treat diabetic retinopathy in patients with diabetic macular edema.
The FDA approved ranibizumab...
02/09/2015
First Report Managed Care

Newsfeed

News
Balancing Medicare Advantage Denials for Patients With Diabetic Macular Edema
03/04/2024

Emry Lloyd

Emry Lloyd
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of necessary medical service claims are denied by health care providers; policymakers want to balance these denials for those who need care and how this affects patients with diabetic macular edema.
Every year, millions of...
03/04/2024
First Report Managed Care
News
Subthreshold Micropulse Laser Equivalent to Standard Laser Therapy for DME
01/10/2024
Jolynn Tumolo
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser therapy was comparable in both efficacy and cost to standard laser therapy in patients with diabetic macular edema (DME) with central retinal thickness less than 400 μm, according to a noninferiority trial...
Subthreshold micropulse laser...
01/10/2024
First Report Managed Care
News
Response to First Anti-VEGF Injection for DME Predicts Long-term Effects of Therapy
11/21/2022
Jolynn Tumolo
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial outcomes were a predictor of long-term results, study authors followed patients with diabetic macular edema for several months to assess their responses to anti-vascular endothelial growth factor injections.
To understand whether initial...
11/21/2022
First Report Managed Care
News
Retinal Thickness Lower With Intravitreal Steroids for Diabetic Macular Edema
11/09/2022
Jolynn Tumolo
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the importance of a continual reevaluation of the role of intravitreal steroids in diabetic macular edema management,” wrote study authors.
“Our results reinforce the...
11/09/2022
First Report Managed Care
News
Treatment More Effective Than Laser Photocoagulation for Improving Diabetic Macular Edema
10/24/2022
Jolynn Tumolo
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy improved visual and anatomical outcomes in patients with diabetic macular edema.
Findings showed targeted therapy...
10/24/2022
First Report Managed Care
News
Anti-VEGF Treatment Changes Aqueous Cytokine Levels in Patients With DME
10/21/2022
Edan Stanley
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the alterations of different aqueous humor cytokine concentrations after intravitreal antivascular endothelial growth factor treatment in patients with diabetic macular edema.
Researchers examined the...
10/21/2022
First Report Managed Care
News
Cataract Surgery Outcomes Unaffected by Intravitreal Aflibercept for Diabetic Macular Edema
09/21/2022
Jolynn Tumolo
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept, gender, and other factors "did not interfere with the morphological and functional outcomes of diabetic macular edema in cataract surgery,” researchers said.
Intravitreal aflibercept,...
09/21/2022
First Report Managed Care
News
Intravitreal VEGF Inhibitors Associated With HbA1c Reduction for Patients With DME
09/14/2022
Maria Asimopoulos
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact of intravitreal aflibercept and ranibizumab on estimated glomerular filtration rates and glycated hemoglobin A1c for patients with diabetic macular edema.
Recent findings show the impact...
09/14/2022
First Report Managed Care
News
Preoperative Bevacizumab Benefits Patients With Diabetes With Vitreous Hemorrhage Without Tractional Detachment
06/02/2022
Jolynn Tumolo
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood of developing diabetic macular edema after receiving preoperative bevacizumab.
Patients had a lower likelihood...
06/02/2022
First Report Managed Care
News
Study Compares 3 Drugs for Diabetic Macular Edema
02/19/2015
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs for the treatment of diabetic macular edema—bevacizumab, afilbercept, and ranibizumab—to determine which is the most effective treatment for patients with moderate vision loss.
A recent study compared 3 drugs...
02/19/2015
First Report Managed Care
News
Keratoconus Appears to be Associated With Demodex Mites
05/16/2024
Jolynn Tumolo
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
Keratoconus, an eye disorder that leads to gradual curvature of the cornea, may be associated with Demodex infestation, suggests a small study published in the Oman Journal of Ophthalmology.
Keratoconus, an eye disorder...
05/16/2024
First Report Managed Care
News
Hospital Costs May Be Higher for Patients With Private Insurance
05/14/2024
Hannah Musick
A recent research report reveals that individuals with private health insurance pay 254% more for hospital procedures than Medicare rates, leading to potentially increased costs for millions of Americans.
A recent research report reveals that individuals with private health insurance pay 254% more for hospital procedures than Medicare rates, leading to potentially increased costs for millions of Americans.
A recent research report reveals...
05/14/2024
First Report Managed Care
News
Study Finds No Treatment-Related Adverse Events in Boys Treated With Purified FIX Concentrate
05/09/2024
Jolynn Tumolo
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX) concentrate was effective in treating and preventing bleeding episodes in real-world pediatric patients 6 years and younger with hemophilia B, according to a study published in the Journal of Blood Medicine.
Purified factor IX (FIX)...
05/09/2024
First Report Managed Care
News
Demodex Infestation Found in 9 of 10 Eye Clinic Patients Using 2-Minute Technique
05/09/2024
Jolynn Tumolo
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the eyelashes of 94% of patients examined with a simple diagnostic technique at a standard ophthalmic practice, according to a study published online in the journal Clinical Ophthalmology.
Demodex mites were found in the...
05/09/2024
First Report Managed Care
News
Debate Emerges Over FDA's Plan to Regulate Laboratory Medical Tests
05/03/2024
Hannah Musick
The FDA's new regulations on laboratory-developed tests have sparked debate over access to innovative tests and patient care in the medical field, with opponents arguing that increased oversight could hinder the development of crucial new...
The FDA's new regulations on laboratory-developed tests have sparked debate over access to innovative tests and patient care in the medical field, with opponents arguing that increased oversight could hinder the development of crucial new...
The FDA's new regulations on...
05/03/2024
First Report Managed Care
Conference Coverage
What Does Value Mean to You: Value-Based Contracting Expert Insights
05/02/2024
Danielle Sposato
A panel at Asembia 2024 delved into the complexities of value-based contracting in health care, emphasizing the need for collaboration among stakeholders to address key issues and improving access to medicines for patients.
A panel at Asembia 2024 delved into the complexities of value-based contracting in health care, emphasizing the need for collaboration among stakeholders to address key issues and improving access to medicines for patients.
A panel at Asembia 2024 delved...
05/02/2024
First Report Managed Care
Conference Coverage
Expanding Pharmacists’ Role in Providing Clinical Care: Addressing Public Health Challenges
05/02/2024
Danielle Sposato
Panelists from various backgrounds discuss the critical role of pharmacists in addressing public health challenges such as HIV/AIDS and advocating for expanded clinical care and reimbursement pathways to improve health outcomes in communities.
Panelists from various backgrounds discuss the critical role of pharmacists in addressing public health challenges such as HIV/AIDS and advocating for expanded clinical care and reimbursement pathways to improve health outcomes in communities.
Panelists from various...
05/02/2024
First Report Managed Care
Conference Coverage
Addressing Cost & Accessibility for Innovative Medicines: GLP-1s and Beyond
05/02/2024
Danielle Sposato
The rapid pace of innovation, rising costs of prescription drugs, and the need for transparency to ensure access and affordability in the pharmaceutical industry are discussed in a session at Asembia 2024.
The rapid pace of innovation, rising costs of prescription drugs, and the need for transparency to ensure access and affordability in the pharmaceutical industry are discussed in a session at Asembia 2024.
The rapid pace of innovation,...
05/02/2024
First Report Managed Care
Conference Coverage
Rare Orphan, Oncology, and Specialty Drugs in Development: Review of Therapeutic Areas, Designations, and Launch Projections
05/01/2024
Danielle Sposato
The specialty pharmacy pipeline was the subject of one of many informative sessions at the annual Asembia Summit this year. Key insights were shared about current drugs in the pipeline according to their drug designations, the phase of each...
The specialty pharmacy pipeline was the subject of one of many informative sessions at the annual Asembia Summit this year. Key insights were shared about current drugs in the pipeline according to their drug designations, the phase of each...
The specialty pharmacy pipeline...
05/01/2024
First Report Managed Care
Conference Coverage
Specialty Pharmaceuticals Pipeline: Biologic and Biosimilar Approvals and Projected Developments
04/29/2024
Hannah Musick
Explore the latest trends and developments in the specialty pharmaceutical pipeline, including key legal matters, FDA issues, notable approvals, and potential biosimilar savings projected for the next decade as shared in a 2024 AMCP session.
Explore the latest trends and developments in the specialty pharmaceutical pipeline, including key legal matters, FDA issues, notable approvals, and potential biosimilar savings projected for the next decade as shared in a 2024 AMCP session.
Explore the latest trends and...
04/29/2024
First Report Managed Care

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use

Advertisement

Advertisement